HC Wainwright Weighs in on Alumis’ Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Alumis in a research report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.07) per share for the quarter, up from their previous estimate of ($1.29). HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.39) EPS.

A number of other research analysts have also recently issued reports on the company. Oppenheimer began coverage on Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Alumis has a consensus rating of “Buy” and a consensus target price of $26.00.

Alumis Price Performance

Shares of ALMS stock opened at $4.70 on Friday. Alumis has a 12-month low of $3.18 and a 12-month high of $13.53. The firm has a fifty day moving average of $5.43 and a 200-day moving average of $8.38.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in shares of Alumis in the 3rd quarter valued at approximately $27,000. Wells Fargo & Company MN lifted its stake in Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock valued at $69,000 after acquiring an additional 3,823 shares during the last quarter. Northern Trust Corp increased its stake in shares of Alumis by 4.3% during the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company’s stock worth $875,000 after purchasing an additional 4,587 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company’s stock valued at $891,000 after purchasing an additional 4,808 shares during the period. Finally, Barclays PLC lifted its stake in Alumis by 33.9% in the 4th quarter. Barclays PLC now owns 24,581 shares of the company’s stock valued at $193,000 after purchasing an additional 6,221 shares during the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.